

# CarvOlympics: Investing in the Autonomous Future of Cardiovascular Medicine

A de-risked platform poised to capture the **€23B+** market for cardiac valve and stroke treatment.



# Our Mission: Make Every Cathlab as Autonomous and Safe as an Airplane Cockpit



**The Past: High-Risk,  
Manual Art**

**The Past:  
High-Risk, Manual**



**The Future: High-Precision,  
Autonomous Science**

**The Future: High-Precision,  
Autonomous Science**

We are transforming complex, high-risk manual procedures into a standardized, data-driven science. This leap in safety, precision, and efficiency will democratize access to life-saving care for millions.



# Millions of Patients Suffer Needlessly Due to Systemic Bottlenecks.



## Aortic Stenosis (TAVI)

**17%**

of eligible patients are treated.

Poor valve positioning leads to a 2x higher mortality rate in low & mid-volume centers.



## Ischemic Stroke (MT)

**5%**

of patients receive emergency clot removal (Mechanical Thrombectomy).

A critical shortage of specialized neurovascular centers and trained clinicians is the key barrier to care.




## Mitral Regurgitation (TMVR)

**High-Risk Surgery  
Dominates**

The majority of patients are treated with high-risk open-heart surgery, creating a massive unmet need for a scalable, minimally invasive solution.



# One Integrated Platform to Democratize Two of Medicine's Most Complex Procedures




# Targeting a Massive, Growing €23 Billion Market Poised for Disruption

## €23 Billion

Total Addressable Market (TAM) by 2030 (Cardiac Valves & Stroke)

### Market Breakdown & Projections



### Key Market Drivers



Aging Population




Shift to Minimally Invasive Procedures



Value-Based Healthcare  
Demanding Better Outcomes



# A Proven 'Razor-and-Blades' Model Engineered for Rapid Adoption and High Margins.



# Investment Pillar 1: De-risked by Unparalleled Market Validation



Edwards Lifesciences®

**€15M Upfront Non-Dilutive Funding from Edwards Lifesciences, the world leader in cardiac valves.**



## Validation

Exclusive option and licensing agreements secured for our KALIOS and EPYGON mitral valve technologies.




## Implication

*This is not just capital; it is the ultimate validation of our technology, IP, and team from a potential future acquirer. It signals a clear path to market and exit.*



# Investment Pillar 2: De-risked by a Clear Regulatory Path with Near-Term Revenue





# Investment Pillar 3: De-risked by Proven MedTech Builders with Multiple Successful Exits

## The Founder: Truffle Capital

24-year track record of building and exiting BioMedTech companies.



Acquired by Boston Scientific for **\$435M**



Acquired by Stryker for **\$221M**

## The Management Team & Board

Deep domain expertise from the world's leading MedTech companies.

Medtronic




**Liane Teplitsky**  
(Exec Chair, Abbott)

**Sébastien Ladet**  
(CEO, Medtronic)


**Dr. Howard Herrmann**  
(CMO, UPenn)



# Our Unique Focus on Autonomy Creates a Defensible Moat



**First-Mover in Full Autonomy:** We are building the first fully autonomous system, not just an assistive tool.



**Unified Platform:** Our technology spans both TAVI and Stroke, multiplying market access.



**Protected IP:** A robust moat of 50+ patent families across all products.



# Disciplined Capital to Unlock Sequential Value Creation



## The Ask

### Funding Round

Pre-IPO / Consolidation

### Total Goal (2025-2027)


**€181 Million**

### This Ask

Seeking an Anchor Investor for a **€30 Million** round (minimum ticket of €15M).



## Use of Proceeds





# Dual Exit Pathways with a Projected Aggregate Value of €1.8 Billion



**M&A Scenario (Target 2027-2029)**

**~€1.8 Billion**

Projected Aggregate Value

Likely Acquirers: **Edwards Lifesciences**  
(noting the existing strategic relationship),  
Medtronic, Boston Scientific, Johnson  
& Johnson.



**IPO Scenario (Target 2027/2028)**

**NASDAQ Listing**

**\$1 Billion+**

Upon reaching commercial stage.



# CarvOlympics: A Compelling, De-risked Investment in the Future of Medicine.



1. **Revolutionary Vision:** Creating the new 'autonomous' standard of care in a **€23B+ market** with massive unmet needs.



2. **De-risked Technology:** Validated by a **€15M deal with market leader Edwards Lifesciences** and successful pre-clinical trials.



3. **De-risked Commercial Path:** Near-term revenue from **FDA-submitted software** (Dec 2024) and a capital-efficient 'razor-and-blades' model.



4. **De-risked Execution:** Led by a world-class team from Truffle Capital, with a track record of billion-dollar MedTech exits (e.g., **Symetis, \$435M**).



5. **Clear Path to Liquidity:** A defined 3-4 year M&A or IPO exit strategy with a projected **€1.8 Billion aggregate value**.



# Join Us in Building the Future of Interventional Medicine

## Next Steps

We invite you to the next stage of our process, which includes:

- 📁 Access to our comprehensive Data Room.
- 👤 A detailed discussion with our executive management team.






# Appendix: Key Data & Milestones




## TAVIPILOT Software

- **Technology:** 6<sup>th</sup> Gen AI model trained on 5,500+ patient database.
- **Clinical Validation:** Detection error of  $\leq 2\text{mm}$  in 100% of patients;  $\leq 1\text{mm}$  in 92%.
- **Regulatory:** FDA 510(k) submitted Dec 2024.



## KALIOS (Mitral Repair)

- **Clinical Data:** 26 patients implanted in pivotal trial. Primary efficacy endpoint met at 1 year.
- **Regulatory:** FDA did not request additional patients (Sept 2024), de-risking the path to De Novo submission.



## TAVIPILOT Robot

- **Milestones:** Successful world-first robotic TAV delivery in animal (2024).
- **Next Step:** First-in-human planned for 2025.



## Intellectual Property

- **Platform Protection:** A robust portfolio of 50+ patent families across the entire platform, covering software, robotics, valves, and microrobotics.



## SASHA (Stroke Micro-robot)

- **Milestones:** 11 successful animal labs demonstrating autonomous navigation, anchoring, and retrieval.